CEACAM5 was first described in 1965 as a gastrointestinal oncofetal antigen [10], but is now known to be overexpressed in a majority of carcinomas, including those of the gastrointestinal tract, the respiratory and genitourinary systems, and breast cancer [11-15]. The gene discussed is CEACAM5; the disease is carcinoma.